Unprecedented results against a stubbornly hard-to-treat cancer are boosting optimism that other challenging tumours will be next.

Immunotherapies have transformed cancer treatment by harnessing the immune system to recognize and eliminate malignant cells, offering durable clinical benef...

Under the leadership of Josep Tabernero, VHIO is an internationally recognized cancer center. Its multidisciplinary, collaborative model drives scientific progress and innovative cancer treatments.

MYC performs a dual role in DNA Damage Response (DDR), promoting genomic instability through replication stress, R-loop formation, and topoisomerase-mediated...

Giuntini et al. demonstrate that Omomyc, the only direct MYC inhibitor currently in phase 2 clinical trials, causes DNA damage and synergizes with PARPis in triple-negative breast cancer. Their findin...

Nature Reviews Drug Discovery - Oncogene MYC has been considered ‘undruggable’ for many decades. This Review provides an overview of the various strategies to inhibit MYC, focusing on...